Menu Search
Equities

IPCA Laboratories Ltd

IPCALAB:NSI

IPCA Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,591.35
  • Today's Change18.40 / 1.17%
  • Shares traded295.56k
  • 1 Year change+46.51%
  • Beta0.3721
Data delayed at least 15 minutes, as of Nov 22 2024 10:23 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy3
Outperform5
Hold2
Sell2
Strong Sell0

Share price forecast in INR

The 13 analysts offering 12 month price targets for IPCA Laboratories Ltd have a median target of 1,700.00, with a high estimate of 1,930.00 and a low estimate of 951.00. The median estimate represents a 6.62% increase from the last price of 1,594.50.
High21.0%1,930.00
Med6.6%1,700.00
Low-40.4%951.00

Dividends

In 2024, IPCA Laboratories Ltd reported a dividend of 4.00 INR, equaling last years dividend. The 8 analysts covering the company expect dividends of 5.31 INR for the upcoming fiscal year, an increase of 32.73%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in INR

On Nov 14, 2024, IPCA Laboratories Ltd reported 2nd quarter 2025 earnings of 9.05 per share. This result exceeded the 8.50 expectation of the one analyst covering the company and exceeded last year's 2nd quarter results by 58.22%.
The next earnings announcement is expected on May 05, 2025.
Average growth rate+49.76%
IPCA Laboratories Ltd reported annual 2024 earnings of 21.57 per share on May 29, 2024.
Average growth rate+8.89%
More ▼

Revenue history & estimates in INR

Ipca Laboratories Limited had 2nd quarter 2025 revenues of 23.55bn. This bettered the 23.21bn consensus of the 7 analysts covering the company. This was 48.33% above the prior year's 2nd quarter results.
Average growth rate+3.86%
Ipca Laboratories Limited had revenues for the full year 2024 of 77.05bn. This was 23.39% above the prior year's results.
Average growth rate+13.66%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.